Abstract：Objective To evaluate the dose response of patients with ⅠE stage non-conjunctival primary ocular adnexal mucosa associated lymphoid tissue lymphoma(POAML) treated with primary radiotherapy.Methods Clinical data on thirty-three patients(42 eyes) with stage Ⅰnon-conjunctival POAML treated between November 2003 and Match 2012 were retrospectively studied.Results For all the patients, the local control rate was 100% at the dose of 18 Gy and 27 Gy, while the response rate was 31% and42.9%(P=0.258)respectively as measured with the WHO criteria. However, the response rate was 28.6% and38.1%(P=0.355)respectively as measured with the RECIST criteria. For patients of non-conjunctival POAML treated at the dose of ≥30.6 Gy and 27 Gy, the five-year overall survival(OS) rate was 100% and 95.7% respectively (P=0.8578), and the five-year progression-free survival(PFS) rate was 83.3% and 91.1% respectively (P=0.6497).Conclusions The prescribed dose of 27 Gy for non-conjunctival POAML seems to be effective. Prospective clinical studies should be carried out to define the optimal dose for POAML.
Lazzarino M, Morra E, Rosso R, et al. Clinicopathologic and immunologic characteristics of non Hodgkin’s lymphoma presenting in the orbit[J]. Cancer,1985,55(9):1907-1912.
[2]
Bairey O, Kremer I, Rakowsky E, et al. Orbital and adnexal involvement in systemic non-Hodgkin’s lymphoma[J]. Cancer,1994,73(9):2395-2399.
[3]
Freeman C, Berg J W, Cutler S J. Occurrence and prognosis of extranodal lymphomas[J]. Cancer,1972,29(1):252-260.
[4]
White W L,Ferry J A,Harris N L,et al.Ocular adnexal lymphoma: a clinicopathologic study with identi cation of lymphomas of mucosa-associated lymphoid tissue type[J].Ophthalmology,1995,102(12):1994-2006.
[5]
McKelvie P A, McNab A, Francis I C, et al. Ocular adnexal lymphoproliferative disease: a series of 73 cases[J].Clin Experiment Ophthalmol,2001,29(6):387-393.
[6]
Meunier J, Lumbroso-Le Rouic L, et al. Ophthalmologic and intraocular non-Hodgkin’s lymphoma: a large single centre study of initial characteristics, natural history, and prognostic factors[J]. Hematol Oncol,2004,22(4):143-158.
[7]
Ferry J A, Fung C Y, Zukerberg L, et al. Lymphoma of the ocular adnexa: a study of 353 cases[J]. Am J Surg Pathol,2007,31(2):170-184.
[8]
Nakata M, Matsuno Y, Katsumata N, et al. Histology according to the Revised European-American Lymphoma Classification significantly predicts the prognosis of ocular adnexal lymphoma[J]. Leuk Lymphoma,1999,32(5-6):533-543.
[9]
Mannami T,Yoshino T, Oshima K, et al. Clinical, histopathological, and immunogenetic analysis of ocular adnexal lymphoproliferative disorders: characterization of MALT lymphoma and reactive lymphoid hyperplasia[J]. Mod Pathol,2001,14(7):641-649.
[10]
Cho E Y, Han J J, Ree H J, et al. Clinicopathologic analysis of ocular adnexal lymphomas: extranodal marginal zone B-cell lymphoma constitutes the vast majority of ocular lymphomas among Koreans and affects younger patients[J]. Am J Hematol,2003,73(2):87-96.
[11]
Lee J L, Kim M K, Lee K H, et al. Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue type of the orbit and ocular adnexa[J]. Ann Hematol, 2005,84(1):13-18.
[12]
Woo J M, Tang C K, Rho M S, et al. The clinical characteristics and treatment results of ocular adnexal lymphoma[J]. Korean J Ophthalmol,2006,20(1):7-12.
[13]
Yoon J S,Ma K T,Kim S J,et al.Prognosis for patients in a Korean population with ocular adnexal lymphoproliferative lesions[J].Ophthal Plast Reconstr Surg,2007,23(2):94-99.
[14]
Le Q T, Eulau S M, George T I, et al. Primary radiotherapy for localized orbital MALT lymphoma[J]. Int J Radiat Oncol Biol Phys,2002,52(3): 657-663.
[15]
Tsang R W, Gospodarowicz M K, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome[J]. J Clin Oncol,2003,21(22):4157-4164.
[16]
Fung C Y, Tarbell N J, Lucarelli M J, et al. Ocular adnexal lymphoma: clinical behavior of distinct world health organization classification subtypes[J]. Int J Radiat Oncol Biol Phys,2003,57(5): 1382-1391.
[17]
Hasegawa M, Kojima M, Shioya M, et al. Treatment results of radiotherapy for malignant lymphoma of the orbit and histopathological review according to the WHO classification[J]. Int J Radiat Oncol Biol Phys,2003,57(1):172-176.
[18]
Uno T, Isobe K, Shikama N, et al. Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa. A multiinstitutional, retrospective review of 50 patients[J]. Cancer,2003,98(4):865-871.
[19]
Lee J L, Kim M K, Lee K H, et al. Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue-type of the orbit and ocular adnexa[J]. Ann Hematol,2005,84(1):13-18.
[20]
Aviles A, Neri N, Calva A, et al. Addition of a short course of chemotherapy did not improve outcome in patients with localized marginal B-cell lymphoma of the orbit[J]. Oncology,2006,70(3):173-176.
[21]
Suh C O, Shim S J, Lee S W, et al. Orbital marginal zone B-cell lymphoma of MALT: radiotherapy results and clinical behavior[J]. Int J Radiat Oncol Biol Phys, 2006,65(1):228-233.
Yamashita H,Nakagawa K,Asari T,et al.Radiotherapy for 41 patients with stages I and II MALT lymphoma: a retrospective study[J].Radiother Oncol,2008,87(3):412-417.
[24]
Nam H,Ahn Y C,Kim Y D,et al.Prognostic significance of anatomic subsites:results of radiation therapy for 66 patients with localized orbital marginal zone B cell lymphoma[J].Radiother Oncol,2009,90(2):236-241.
[25]
Son S H, Choi B O, Kim G W, et al. Primary radiation therapy in patients with localized orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) [J]. Int J Radiat Oncol Biol Phys,2010,77(1):86-91.
[26]
Hata M, Omura M, Koike I, et al. Treatment effects and sequelae of radiation therapy for orbital mucosa-associated lymphoid tissue lymphoma[J]. Int J Radiat Oncol Biol Phys, 2011,81(5):1387-1393.
[27]
Goda J S, Le L W, Lapperriere N J, et al. Localized orbital mucosa-associated lymphoma tissue lymphoma managed with primary radiation therapy: efficacy and toxicity[J]. Int J Radiat Oncol Biol Phys,2011,81(4):e659-666.
[28]
Hashimoto N, Sasaki R, Nishimura H, et al. Long-term outcome and patterns of failure in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy[J]. Int J Radiat Oncol Biol Phys,2012,82(5): 1509-1514.
[29]
Ohja S, Nakamura K, Shioyama Y, et al. Treatment outcome of radiotherapy for localized primary ocular adnexal MALT lymphoma-prognostic effect of the AJCC Tumor-Node-Metastasis clinical staging system[J].Anticancer Res,2015,35(6):3591-3597.
[30]
Jung S K, Paik J S, Jung S E, et al. Suggestion of response evaluation criteria in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma (OAML) [J]. Ann Hematol,2015,94(7):1185-1193
[31]
Gayed I, Eskandari M F, McLaughlin P, et al. Value of positron emission tomography in staging ocular adnexal lymphomas and evaluating their response to therapy[J]. Ophthalmic Surg Lasers Imaging,2007,38(4):319-325.
[32]
Harada K, Murakami N, Kitaguchi M, et al. Localized ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation therapy: a long-term outcome in 86 patients with 104 treated eyes[J]. Int J Radiat Oncol Biol Phys,2014,88(3):650-654.
2016, Vol. 27 
